Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines

Pediatric Infectious Disease Journal

Volumn 25, Issue 4, 2006, Pages 287-292

  Shinefield, Henry ^a   Black, Steve ^b   Thear, Marci ^c   Coury, Daniel ^d   Reisinger, Keith ^e   Rothstein, Edward ^f   Xu, Jin ^c   Hartzel, Jonathan ^c   Evans, Barbara ^c   Digilio, Laura ^c   Schädel, Florian ^c   Brown, Michelle L Huffman ^c   Kuter, Barbara ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e Primary Physicians Research   (United States)

^f Pennridge Pediatric Associates   (United States)

Author keywords

COMVAX; Immunization; M M R II; Measles; Mumps; ProQuad; Rubella; TRIPEDIA; Vaccine; Varicella; VARIVAX

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEMAGGLUTININ; M M R; MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS RUBELLA VARICELLA VACCINE; PERTUSSIS TOXIN; PROQUAD; UNCLASSIFIED DRUG; VIRAVAX;

ANTIBODY RESPONSE; ARTICLE; BRONCHIOLITIS; CHICKENPOX; CLINICAL TRIAL; COMPARATIVE STUDY; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAPER DERMATITIS; DIPHTHERIA; DRUG CONJUGATION; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE CONVULSION; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MEASLES; MULTICENTER STUDY; MUMPS; NORMAL HUMAN; OPEN STUDY; OTITIS MEDIA; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINORRHEA; RISK ASSESSMENT; RUBELLA; SINUSITIS; STATISTICAL SIGNIFICANCE; SWEAT GLAND DISEASE; SYSTEMIC DISEASE; TETANUS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHICKENPOX VACCINE; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; MEASLES-MUMPS-RUBELLA VACCINE; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 33645546472     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000207857.10947.1f     Document Type: Article

References (15)

1. General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR. 2002;51(RR-2):1-36.
2. National, state, and urban area vaccination levels among children aged 19-35 months: United States, 2003. MMWR. 2004;53(29):658-661.
3. Watson BM, Laufer DS, Kuter BJ, Stachle B, White CJ. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMRV) in healthy children. J Infect Dis. 1996;173:731-734.
4. White CJ, Stinson D, Staehle B, et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Clin Infect Dis. 1997;24:925-931.
5. Shehab ZM, Brunell PA, Cobb E. Epidemiological standardization of a test for susceptibility to mumps. J Infect Dis. 1984;149:810-812.
6. Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J. 1996;15:687-692.
7. Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW. Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods. 1986;14:177-188.
8. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol. 1990;32:189-193.
9. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assay suitable for assessing immune responses to live varicella vaccine. Vaccine. 1991;9:111-116.
10. Ward JI, Greenberg DP, Anderson PW, et al. Variable quantitation of Haemophilus influenza type b anticapsular antibody by radioantigen binding assay. J Clin Microbiol. 1988;26:72-78.
11. Hollinger FB, Adam E, Heiberg D, Melnick JL. Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis: 1981 International Symposium. Philadelphia, PA: The Franklin Institute Press: 1982:451-466.
12. Aggerbeck H, Heron I. Improvement of a Vero cell assay to determine diphtheria antitoxin content in sera. Biologicals. 1991;19:71-76.
13. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
14. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella, and varicella vaccine in healthy children. Pediatr Infect Dis J. In press.
15. Redd SC, Markowitz LE, Katz SL. Measles. In: Plotkin SA, Orenstein WA. Vaccines. 3rd ed. Philadelphia, PA: W. B. Saunders; 1999:222-266.